Lymphoma Action

LOTIS-5: A phase 3 trial of loncastuximab tesirine and rituximab in people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

Trial

… plus antibody therapy for people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The trial … tesirine plus rituximab in people with relapsed or refractory DLBCL. Part 2 is to compare loncastuximab … rituximab, in people with DLBCL that has not responded (refractory) or has come back (relapsed) after previous …

REFRACT: A phase 2 trial comparing new treatments to standard treatment in relapsed or refractory follicular lymphoma

Trial

… in patients with FL which has either failed to respond to (refractory) or returned after (relapsed) treatment. Patients … Who can enter Adults with FL which has relapsed or become refractory to at least one previous treatment, and have … if they have better outcomes in patents with relapsed or refractory follicular lymphoma (FL) . You can share the …

PRiZM+: A phase 1 trial of zanubrutinib in people with relapsed or refractory primary central nervous system lymphoma

Trial

… which has come back after (relapsed) or not responded to (refractory) treatment may be eligible for this trial … trial is testing zanubrutinib in people with relapsed or refractory primary central nervous system (CNS) lymphoma. You … A phase 1 trial of zanubrutinib in people with relapsed or refractory primary central nervous system lymphoma …

NAVAL-1: a phase 2 trial of nanatinostat with valganciclovir in Epstein-Barr Virus-Positive relapsed and refractory lymphomas

Trial

… back (relapsed) or not responded to previous treatment (refractory). Who can enter Adults with EBV+ lymphomas … and valganciclovir in people with relapsed and refractory Epstein-Barr virus-positive (EBV+) lymphomas. You … valganciclovir in Epstein-Barr Virus-Positive relapsed and refractory lymphomas …

BGB-11417 (WM): A phase 2 trial of BGB-11417 in people with relapsed or refractory Waldenstrom’s Macroglobulinaemia

Trial

… when given to patients with WM which has relapsed, or is refractory to current treatment options. The main goals are … block this protein. Who can enter People with relapsed or refractory WM may be eligible for this trial. Locations … which has come back after (relapsed) , or not responded (refractory) to treatment. You can share the following …

AZD7789: A phase 1/2 trial of AZD7789 in people with relapsed or refractory classical Hodgkin lymphoma

Trial

… back (relapsed) or not responded to previous treatment (refractory lymphoma). This trial involves the participant … … This trial is testing AZD7789 in people with relapsed or refractory classical Hodgkin lymphoma. You can share the … A phase 1/2 trial of AZD7789 in people with relapsed or refractory classical Hodgkin lymphoma …

Kite: A trial testing KITE-363 and KITE-753 in people with relapsed and refractory B-cell lymphoma

Trial

… KITE-363 and KITE-753 in patients with relapsed or refractory B-cell lymphoma. These are both CAR-T therapies . … least one measurable lesion which has relapsed or become refractory to treatment, and who have adequate organ and bone … KITE-363 and KITE-753 in adults with relapsed or refractory B-cell lymphoma. You can share the following …

MK-4280A-008: A phase 3 trial of favezelimab/pembrolizumab compared to chemotherapy in relapsed or refractory classical Hodgkin lymphoma

Trial

… back (relapsed) or not responded to previous treatment (refractory). It will also test the safety profile and side … aged over 18 with classical HL which has relapsed or is refractory and have exhausted all known treatment options may … favezelimab/pembrolizumab in people with relapsed or refractory classical Hodgkin lymphoma. You can share the …

BGB-11417 (MCL): A trial testing the treatment BGB-11417 in patients with relapsed or refractory mantle cell lymphoma

Trial

… BGB-11417 in monotherapy in patients with relapsed or refractory MCL . The trial consists of two parts: Part 1: … recommended dose Who can enter Adults with relapsed or refractory MCL who have had previous systemic treatment may … BGB-11417 monotherapy in patients with relapsed or refractory mantle cell lymphoma (MCL). You can share the …

DTP3: A phase 1/2 trial of DTP3 in people with relapsed or refractory diffuse large B cell lymphoma (DLBCL)

Trial

… the future. Who can enter Anyone over 16 with relapsed or refractory DLBCL may be eligible for this trial. Locations … testing a new medication, DTP3, in people with relapsed or refractory diffuse large B cell lymphoma (DLBCL) You can … DTP3: A phase 1/2 trial of DTP3 in people with relapsed or refractory diffuse large B cell lymphoma (DLBCL) …